key: cord-0426667-j1ddgc26
authors: Wu, Yang; Qi, Ting; Wang, Huanwei; Zhang, Futao; Zheng, Zhili; Phillips-Cremins, Jennifer E.; Deary, Ian J.; McRae, Allan F.; Wray, Naomi R.; Zeng, Jian; Yang, Jian
title: Promoter-anchored chromatin interactions predicted from genetic analysis of epigenomic data
date: 2019-12-17
journal: bioRxiv
DOI: 10.1101/580993
sha: 63b1e2447b4b75a78169e1cde1ab200bbe9abdd9
doc_id: 426667
cord_uid: j1ddgc26

Promoter-anchored chromatin interactions (PAIs) play a pivotal role in transcriptional regulation. Current high-throughput technologies for detecting PAIs, such as promoter capture Hi-C, are not scalable to large cohorts. Here, we present an analytical approach that uses summary-level data from cohort-based DNA methylation (DNAm) quantitative trait locus (mQTL) studies to predict PAIs. Using mQTL data from human peripheral blood (n=1,980), we predicted 34,797 PAIs which showed strong overlap with the chromatin contacts identified by previous experimental assays. The promoter-interacting DNAm sites were enriched in enhancers or near expression QTLs. Genes whose promoters were involved in PAIs were more actively expressed, and gene pairs with promoter-promoter interactions were enriched for co-expression. Integration of the predicted PAIs with GWAS data highlighted interactions among 601 DNAm sites associated with 15 complex traits. This study demonstrates the use of mQTL data to predict PAIs and provides insights into the role of PAIs in complex trait variation.

Genome-wide association studies (GWASs) in the past decade have identified tens of thousands 37 of genetic variants associated with human complex traits (including common diseases) at a 38 stringent genome-wide significance level 1,2 . However, most of the trait-associated variants are 39 located in non-coding regions 3, 4 , and the causal variants as well as their functional roles in trait 40 etiology are largely unknown. One hypothesis is that the genetic variants affect the trait through 41 genetic regulation of gene expression 4 . Promoter-anchored chromatin interaction (PAI) 5,6 is a key 7 and PHEIDI > 0.01), and 36% were significant after multiple testing correction (PSMR < 4.8 × 10 −6 180 (0.05/10,416) and PHEIDI > 0.01). While the PHM approach requires individual-level genotype and 181 chromatin accessibility data and is less computationally efficient due to the use of Bayesian 182 hierarchical model, our SMR & HEIDI method that requires only summary-level data is more 183 flexible and can be potentially applied to all epigenetic QTL data. S5a ) and can possible contain some of 10 (i.e., the effect of the exposure DNAm site on the outcome site of a predicted PAI) between brain 288 and blood using the rb method 35 . This method does not rely on a P value threshold and accounts 289 for estimation errors in the estimated effects, which is therefore not dependent of the replication 290 sample size. The estimate of rb was 0.527 (SE = 0.0051) for 11,082 PAIs between brain and blood, 291 suggesting a relatively strong overlap in PAI between brain and blood.

It is of note that among the 2,940 blood PAIs replicated at PSMR < 4.51 × 10 −6 and PHEIDI > 0.01 in 294 brain, there were 268 PAIs for which the PAI effects in blood were in opposite directions to those 295 in brain (Supplementary Table 2 ). For example, the estimated PAI effect between the SORT1 and 296 SYPL2 loci was 0.49 in blood and -0.86 in brain. This tissue-specific effect is supported by the 297 differences in gene expression correlation (correlation of expression levels between SORT1 and 298 SYPL2 was -0.07 in whole blood and -0.37 in brain frontal cortex; Pdifference = 0.0018) and the 299 chromatin state of the promoter of SYPL2 (bivalent promoter in blood and active promoter in 300 brain; Fig. S8 ) between brain and blood. Taken together, while there are tissue-specific PAIs, a 301 substantial proportion of the predicted PAIs in blood are consistent with those in brain.

Putative target genes of the disease-associated PIDSs

We have shown above the potential functional roles of the predicted PAIs in transcriptional 305 regulation. We then turned to ask how the predicted PAIs can be used to infer the genetic and 306 epigenetic regulatory mechanisms at the GWAS loci for complex traits and diseases. We have 307 previously reported 1,203 pleiotropic associations between 1,045 DNAm sites and 15 complex 308 traits and diseases by an integrative analysis of mQTL, eQTL and GWAS data using the SMR & 309 HEIDI approach 19 . Of the 1,045 trait-associated DNAm sites, 601 (57.5%) sites were involved in 310 the predicted PAIs related to 299 Pm-PAI genes (Supplementary Table 3 variants affect the trait through genetic regulation of gene expression. One notable example was 321 a PIDS (cg00271210) in an enhancer region predicted to interact in 3D space with the promoter 322 regions of two genes (i.e., RNASET2 and RPS6KA2), the expression levels of both of which were associated with ulcerative colitis (UC) and CD as reported in our previous study 19 (Fig. 6) . The 324 SNP-association signals were consistent across CD GWAS, eQTL, and mQTL studies, suggesting 325 that the genetic effect on CD is likely to be mediated through epigenetic regulation of gene 326 expression. Our predicted PAIs further implicated a plausible mechanism whereby the expression 327 levels of RNASET2 and RPS6KA2 are co-regulated through the interactions of their promoters with 328 a shared enhancer (Fig. 6) , although only 41.5% of the predicted PAIs in this region overlapped 329 with the TADs identified by Hi-C from the Rao et al. study 21 (Fig. S3a) as mentioned above.

According to the functional annotation data derived from the REMC samples, it appears that this 331 shared enhancer is highly tissue-specific and present only in B cell and digestive system that are 332 closely relevant to CD (Fig. 6) . The over-expression of RNASET2 in spleen (Fig. S9) is an additional 333 piece of evidence supporting the functional relevance of this gene to CD. Another interesting 334 example is the ATG16L1 locus (Fig. S10) . We have shown previously that five DNAm sites are in 335 pleiotropic associations with CD and the expression level of ATG16L1 19 . Of these five DNAm sites, 336 three were in an enhancer region and predicted to interact in 3D space with two DNAm sites in 337 the promoter region of ATG16L1 (Fig. S10) , suggesting a plausible mechanism that the genetic 338 effect on CD at this locus is mediated by genetic and epigenetic regulation of the expression level 339 of ATG16L1 through promoter-enhancer interactions.

We have presented an analytical approach on the basis of the recently developed SMR & HEIDI 343 method to predict promoter-anchored chromatin interactions using mQTL summary data. The 344 proposed approach uses DNAm level of a CpG site in the promoter region of a gene as the bait to 345 detect its pleiotropic associations with DNAm levels of the other CpG sites ( Fig. 1) within 2 Mb 346 distance of the focal promoter in either direction. In contrast to experimental assays, such as Hi-347 C and PCHi-C, our approach is cost-effective (because of the reuse of data available from 348 experiments not originally designed for this purpose) and scalable to large sample sizes. Our 349 method utilises a genetic model to perform a Mendelian randomization analysis so that the 350 detected associations are not confounded by non-genetic factors, which is also distinct from the 351 methods that predict chromatin interactions from the correlations of chromatin accessibility 352 measures 14,16 .

Using mQTL summary-level data from human peripheral blood (n = 1,980), we predicted 34,797 355 PAIs for the promoter regions of 4,617 genes. We showed that the predicted PAIs were enriched 356 in TADs detected by published Hi-C and PCHi-C assays and that the PIDS regions were enriched 357 with eQTLs of target genes. We also showed that the PIDSs were enriched in enhancers and that 358 the Pm-PAI genes tended to be more actively expressed than matched control genes. These results 12 demonstrate the functional relevance of the predicted PAIs to transcriptional regulation and the 360 feasibility of using data from genetic studies of chromatin status to infer three-dimensional 361 chromatin interactions. The proposed approach is applicable to data from genetic studies of other 362 chromatin features such as histone modification (i.e., hQTL) 37 or chromatin accessibility (caQTL) 29 .

The flexibility of the method also allowed us to analyse data from different tissues or cell types.

Using summary data from a brain mQTL study (n = 468), we replicated 26.5% of blood PAIs in 365 brain at a very stringent threshold (PSMR < 0.05 / m with m being the number of tests in the 366 replication set and PHEIDI > 0.01) and 66.31% at a less stringent threshold (PSMR < 0.05). Together 367 with an estimate of rb of 0.527 for the correlation of PAI effects between brain and blood, we 368 demonstrated a substantial overlap of the predicted PAIs between blood and brain, in line with 369 the finding from a recent study that cis-mQTLs are largely shared between brain and blood 35 . 

There are several reasons why the overlaps between the predicted PAIs and Hi-C loops were 388 limited. First, Hi-C loops were detected with errors. We observed that the concordances between 389 different Hi-C data sets were very limited (Fig. S11) , consistent with the conclusion from Forcato 390 et al. that the reproducibility of Hi-C loops is low at all resolutions 38 . Second, most (65%) of our 391 predicted PAIs are interactions between DNAm sites within 50 Kb (Fig. S2b) , which are often not 392 well captured by the 3C-based methods due to its low resolution 17 . Third, the chromatin 393 interactions are cell type specific 5 so that differences between the Hi-C loops identified in cell lines 394 and our PAIs identified in whole blood are expected. For the PAIs that were between DNAm sites 13 not located in TADs or Hi-C loops, we have shown specific examples that these predicted PAIs are 396 likely to be functionally interacted ( Fig. 2d and Fig. S3 ), suggesting that these PAIs are likely to 397 be interactions yet to be identified by experimental assays. On the other hand, compared to the 398 loops identified based on 3C-based methods, our predicted PAIs are more likely to be functional 399 interactions due to the use of genetic and regulatory epigenomic data, as evidenced by the 400 observation that our predicted Pm-PAI genes showed stronger enrichment in active gene groups 401 compared to the predicted target genes from the PCHi-C data (Fig. S6) .

There are some limitations of this study. First, chromatin interactions are likely to be tissue-and 404 temporal-specific whereas our PAI analyses were limited to mQTL data from blood and brain 405 owing to data availability and thus were unable to detect PAIs in specific tissues or at different 406 developmental stages. Second, although the sample size of our blood mQTL summary data is large 407 (n = ~2,000), the PAI analysis could be underpowered if the proportion of variance in exposure affected by two sets of causal variants in very high LD, these two DNAm sites will appear to be 415 associated in the SMR analysis and the power of the HEIDI test to reject such an SMR association 416 will be limited because of the high LD 18,19 . However, this phenomenon is likely to be rare given 417 that most of the promoter-anchored DNAm sites were predicted to interact with multiple DNAm 418 sites which are very unlikely to be all caused by distinct sets of causal variants in high LD. Sixth, 419 the predicted PAIs including those falling in chromatin loops and TAD regions were not 420 necessarily functional interactions and need to be validated by functional assays in the future.

Despite these limitations, our study provides a novel computational paradigm to predict PAIs 422 from genetic effects on epigenetic markers with high resolution. Integrating of the predicted PAIs 423 with GWAS, gene expression, and functional annotation data provides novel insights into the 424 regulatory mechanisms underlying GWAS loci for complex traits. The computational framework 425 is general and applicable to other types of chromatin and histone modification data, to further 426 decipher the functional organisation of the genome.

We used summary-level mQTL data to test whether the variation between people in DNAm levels 431 of two CpG sites are associated because of a set of shared causal variants. Mendelian 432 Randomization (MR) is an approach developed to test for the causal effect of an exposure and an 433 outcome using a genetic variant as the instrumental variable 22,23 . Summary-data-based 434 Mendelian Randomization (SMR) is a variant of MR, originally designed to test for association 435 between the expression level of a gene and a complex trait using summary-level data from GWAS 436 and eQTL studies 18 and subsequently applied to test for associations between DNAm and gene 437 expression and between DNAm and complex traits 19 . Here, we applied the SMR analysis to detect 438 associations between DNAm sites. Let x be an exposure DNAm, y be an outcome DNAm, and z be 439 an instrument SNP associated with exposure DNAm (e.g., PmQTL < 5 × 10 −8 ). The SMR estimate of 440 the effect of exposure DNAm on the outcome DNAm (i.e., ' () ) is the ratio of the estimated effect 441 of instrument on exposure ( ' *( ) and that on outcome ( ' *) ), ' () = ' *) / ' *( , where ' *( and ' *) are 442 available from the summary-level mQTL data. We specified the DNAm level of a probe within the 443 promoter region of a gene as the exposure and tested its associations with the DNAm levels of 444 other probes (outcomes) within 2 Mb of the exposure probe ( Fig. 1 and Fig. S1 ). Probe pairs in 445 the same promoter region were not included in the analysis. For a pair of probes in two different 446 promoter regions, the one with higher variance explained by its top associated cis-mQTL was used 447 as the exposure and the other one was used as the outcome. The associations passed the SMR test 448 could possibly be due to linkage (i.e., distinct sets of causal variants in LD, one set affecting the 449 exposure and the other set affecting the outcome), which is less of biological interest in 450 comparison with pleiotropy (i.e., the same set of causal variants affecting both the exposure and 451 the outcome). We then applied the HEIDI (heterogeneity in dependent instruments) test to 452 distinguish pleiotropy from linkage. In brief, the HEIDI test was developed to test against the null 453 hypothesis that the two DNAm sites are affected by the same set of causal variants. This is 454 equivalent to testing whether there is a difference between the ' () estimated from any mQTL i 455 ( ' ()(.) ) and that estimated from the top associated mQTL ( ' ()(012) ). If we define the difference in 456 estimate between ' () at mQTL i and that at top associated mQTL as 4 . = ' ()(.) − ' ()(012) , then 457 for multiple mQTLs (i.e., top 20 associated mQTLs after pruning out SNPs in very strong LD), we 458 have 4~( , ), where 4 = { 4 > , ⋯ , 4 @A } and V is the covariance matrix that can be estimated 459 using summary-level mQTL data and LD information from a reference panel 18 (e.g., the 1KGP-460 imputed HRS 24 data). Therefore, we can test the evidence for heterogeneity through evaluating 461 whether = using an approximate multivariate approach 39 . We rejected the SMR associations 462 with PHEIDI < 0.01. All these analyses have been implemented in the SMR software tool (URLs). and performed the simulation based on these observed distributions (Supplementary Note 2) .

The simulation results showed that P values from both SMR and HEIDI tests were evenly 469 distributed under the null model without inflation or deflation (Fig. S12) . We have made all the 470 PAIs analysis scripts publicly available at GitHub https://github.com/wuyangf7/PAI. The eQTL enrichment analysis was conducted using all the independent cis-eQTLs (m=11,204) 554 from the CAGE 33 study. The independent cis-eQTLs were from SNP-probe associations (P < 5×10 −8 ) 555 after clumping analysis in PLINK 54 followed by a conditional and joint (COJO) analysis in GCTA 55 .

We only retained the cis-eQTLs whose target genes had at least a PIDS and mapped the cis-eQTL 557 to a 10 Kb region centred around each corresponding PIDS of a Pm-PAI gene. To assess the 558 significance of the enrichment, we generated a null distribution by mapping the cis-eQTLs to the 559 same number of control gene-DNAm pairs (strictly speaking, it is the bait DNAm probe in the 560 promoter of a gene together with another non-promoter DNAm probe) randomly sampled (with 561 1,000 repeats) from those included in the PAI analysis with the distance between a control pair 562 matched with that between a Pm-PAI gene and the corresponding PIDS. In addition, we have 563 identified a set of DNAm sites that showed pleiotropic associations with gene expressions in a 564 previous study 19 . We used the same approach as described above to test the significance of 565 enrichment of the gene-associated DNAm sites in the PIDSs. PAI (promoter-enhancer) 

The new NHGRI-EBI Catalog of published genome-wide association 20

Identification of 55,000 Replicated DNA Methylation QTL. Scientific 21